Patent · US Active

Engineered invariant natural killer T (iNKT) cells and methods of making and using thereof

US10927160B2 · kind B2 · utility

1Cited by

0References

19Claims

0Family size

Assignee

The Regents of the University of California · US

Inventors

Lili Yang · Pasadena, US
Drake J. Smith · Los Angeles, US

Key dates

Filing date	Jul 8, 2015
Grant date	Feb 23, 2021
Priority date	—
Expiry date	Mar 13, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2830/48
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are invariant natural killer T (iNKT) cells engineered using hematopoietic stem and progenitor cells (HSPCs) and methods of making and using thereof. Specifically, the engineered cells iNKT are genetically modified to contain at least one exogenous invariant natural killer T cell receptor (iNKT TCR) nucleic acid molecule. Further disclosed are iNKT TCR nucleotide sequences and codon optimized sequences for expression.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.